• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Delivra president & CFO resigns, names new finance VP | Personnel Moves, Nov. 17, 2016

November 17, 2016 By Sarah Faulkner

Delivra president & CFO resigns, names new finance VP | Personnel Moves, Nov. 17, 2016Delivra Corp. (CVE:DVA) said today that president & CFO Chris Schnarr is resigning effective tomorrow and Pascal Attard has been promoted from controller to VP of finance.

Attard has worked as controller for Red Tiger Mining Inc. and manager of McGovern, Hurley, Cunningham LLP prior to joining Delivera in 2015.

The Toronto-based company said it is looking to deepen the technical expertise of its management team for the start of 2017, in the hopes of aggressively pursuing its U.S. expansion strategy. Delivra has started looking for someone with significant experience in consumer healthcare, pharmaceuticals and international licensing.

Delivra develops technologies for the transdermal delivery of pharmaceuticals and natural molecules, rather than oral medications or injections. The company manufactures and sells a line of natural topical creams under the LivRelief brand, marketed for joint and muscle pain, nerve pain, varicose veins, wound healing and sports performance.

“On behalf of the board, I would like to thank Chris for his significant contributions to the company and for building a strong team that will allow us to continue to expand our offering,” chairman & CEO Joseph Gabriele said in prepared remarks. “Our board and management team remains focused on our strategy of monetizing our proprietary LivRelief products while advancing our transdermal platform delivery system as a safe, more effective alternative for a broad range of conditions. Our next phase is to accelerate licensing agreements beyond OTC and to leverage our delivery system in pharmaceutical applications.”

Filed Under: Drug-Device Combinations, Featured, Personnel Tagged With: Delivra Corp

IN CASE YOU MISSED IT

  • Tandem Diabetes Care names successor as CEO Sheridan retires
  • MiniMed names new CMO ahead of planned retirement
  • Insulet earnings trounce Q3 estimates as it narrows guidance
  • Dexcom Q3 earnings top forecasts, as it looks ahead to type 2 coverage
  • Sensonics launches human feasibility study for transmitter-free Eversense CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS